CoChat

Molecular basis for the mechanism of action of an anti‐TACE antibody

Open access
Peng, Li, Cook, Kimberly, Xu, Linda, Cheng, Li, Damschroder, Melissa, Gao, Changshou, Wu, Herren, Dall'Acqua, William F. · 2016 · mAbs

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Abstract

Inhibitors of tumor necrosis factor-α converting enzyme (TACE) have potential as therapeutics for various diseases. Many small molecule inhibitors, however, exhibit poor specificity profiles because they target the highly conserved catalytic cleft of TACE. We report for the first time the molecular interaction of a highly specific anti-TACE antagonistic antibody (MEDI3622). We characterized the binding of MEDI3622 using mutagenesis, as well as structural modeling and docking approaches. We show that MEDI3622 recognizes a unique surface loop of sIVa-sIVb β-hairpin on TACE M-domain, but does not interact with the conserved catalytic cleft or its nearby regions. The exquisite specificity of MEDI3622 is mediated by this distinct structural feature on the TACE M-domain. These findings may aid the design of antibody therapies against TACE.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/19420862.2016.1226716

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. The epitope of MEDI3622 is located in TACE M-domain. (A) Schematic representations of the full-length TACE/ADAM10 chimeric variants. P, M, D, C, TM, and CT stand for prodomain (which is cleaved in mature proteins), metalloproteinase domain, disintegrin-like domain, Cys-rich domain, transmembrane domain, and cytoplasmic domain, respectively. The prodomain and metalloproteinase domain of TACE were replaced with the ADAM10 counterparts to construct the variant LoF_M, and vice versa for the variant GoF_M. (B) Characterization of MEDI3622s binding to full-length TACE chimeric variants by FACS. Protein expression was monitored using anti-TACE polyclonal antibody or anti-ADAM10 monoclonal antibody. The y axis represents side scatter characteristics, and the x axis represents the mean fluorescence intensity. Mock control staining was used to set gates; numbers in gates reflect the percentage of positive cells. MEDI3622 did not bind to the variant LoF_M that encodes the ADAM10 M-domain, but recognized the variant GoF_M when grafting the TACE M-domain into ADAM10.
Figure 1. The epitope of MEDI3622 is located in TACE M-domain. (A) Schematic representations of the full-length TACE/ADAM10 chimeric variants. P, M, D, C, TM, and CT stand for prodomain (which is cleaved in mature proteins), metalloproteinase domain, disintegrin-like domain, Cys-rich domain, transmembrane domain, and cytoplasmic domain, respectively. The prodomain and metalloproteinase domain of TACE were replaced with the ADAM10 counterparts to construct the variant LoF_M, and vice versa for the variant GoF_M. (B) Characterization of MEDI3622s binding to full-length TACE chimeric variants by FACS. Protein expression was monitored using anti-TACE polyclonal antibody or anti-ADAM10 monoclonal antibody. The y axis represents side scatter characteristics, and the x axis represents the mean fluorescence intensity. Mock control staining was used to set gates; numbers in gates reflect the percentage of positive cells. MEDI3622 did not bind to the variant LoF_M that encodes the ADAM10 M-domain, but recognized the variant GoF_M when grafting the TACE M-domain into ADAM10.CC BY-NC · PubMed Central
Figure 2. Determination of the epitope of MEDI3622 at a molecular level. (A) Amino acid alignment of the M-domains of human TACE and ADAM10. Their identical and similar amino acids are shown as green and blue, respectively. Secondary structural elements are shown according to the crystal structure of TACE M-domain,8 with arrows for β-strands, solid boxes for helices and lines for loops. Segments denoted as A-J with dotted lines were swapped between TACE and ADAM10 to construct chimeric variants. (B) Binding characterization of MEDI3622 to TACE/ADAM10 chimeric variants using SPR. Binding was calculated as % binding compared to wild-type TACE after normalization of expression levels using the following formula: [(Response TACE variants MEDI3622/Response TACE wildtype MEDI3622)/(Response TACE variants polyAb/Response TACE wildtype polyAb)] *100. Replacing the segment E with the ADAM10 residues abolished the binding of MEDI3622 (LoF_E), while grafting it to ADAM10 led to the recognition of MEDI3622 (GoF_E). Results represent the means of 3 independent experiments with error bars indicating standard deviations. (C) Determination of MEDI3622s binding to full-length TACE variants by FACS. Expression levels of TACE and its variants were monitored using anti-TACE polyclonal antibody. The y axis represents side scatter characteristics, and the x axis represents the mean fluorescence intensity. Mock control staining was used to set gates; numbers in gates reflect the percentage of positive cells. MEDI3622 did not recognize the full-length TACE chimeric variant encoding for the segment E of ADAM10.
Figure 2. Determination of the epitope of MEDI3622 at a molecular level. (A) Amino acid alignment of the M-domains of human TACE and ADAM10. Their identical and similar amino acids are shown as green and blue, respectively. Secondary structural elements are shown according to the crystal structure of TACE M-domain,8 with arrows for β-strands, solid boxes for helices and lines for loops. Segments denoted as A-J with dotted lines were swapped between TACE and ADAM10 to construct chimeric variants. (B) Binding characterization of MEDI3622 to TACE/ADAM10 chimeric variants using SPR. Binding was calculated as % binding compared to wild-type TACE after normalization of expression levels using the following formula: [(Response TACE variants MEDI3622/Response TACE wildtype MEDI3622)/(Response TACE variants polyAb/Response TACE wildtype polyAb)] *100. Replacing the segment E with the ADAM10 residues abolished the binding of MEDI3622 (LoF_E), while grafting it to ADAM10 led to the recognition of MEDI3622 (GoF_E). Results represent the means of 3 independent experiments with error bars indicating standard deviations. (C) Determination of MEDI3622s binding to full-length TACE variants by FACS. Expression levels of TACE and its variants were monitored using anti-TACE polyclonal antibody. The y axis represents side scatter characteristics, and the x axis represents the mean fluorescence intensity. Mock control staining was used to set gates; numbers in gates reflect the percentage of positive cells. MEDI3622 did not recognize the full-length TACE chimeric variant encoding for the segment E of ADAM10.CC BY-NC · PubMed Central
Figure 3. Structure prediction of MEDI3622. (A) Amino acid sequences of MEDI3622 VH and VL domains. CDRs are shown in bold and underlined according to Chothia definition.29 (B) Modeled 3-dimensional structure of MEDI3622 variable domains, with VH in orange and VL in beige. CDRs are shown in blue. The CDR1L, 2L, 3L, 1H, and 2H of MEDI3622 adopt canonical conformations L1-11A, L2-7A, L3-9A, H1-10A and H2-10B, respectively, and form a relative flat antigen-binding surface with a short CDR3H.
Figure 3. Structure prediction of MEDI3622. (A) Amino acid sequences of MEDI3622 VH and VL domains. CDRs are shown in bold and underlined according to Chothia definition.29 (B) Modeled 3-dimensional structure of MEDI3622 variable domains, with VH in orange and VL in beige. CDRs are shown in blue. The CDR1L, 2L, 3L, 1H, and 2H of MEDI3622 adopt canonical conformations L1-11A, L2-7A, L3-9A, H1-10A and H2-10B, respectively, and form a relative flat antigen-binding surface with a short CDR3H.CC BY-NC · PubMed Central
Figure 4. Proposed binding mode of MEDI3622. (A) Three-dimensional model of MEDI3622 bound to TACE. The identified epitope of MEDI3622 (P366-N381) (cyan) adopts a β-hairpin loop conformation projecting from the central body of M-domain (magenta). TACE residues Y370 and Y379 (cyan) along with conserved histidines H405, H409, H415 (yellow) are shown in sticks. The Zn ion is shown as a green sphere. MEDI3622 (VH in orange, VL in beige) binds to TACE through interacting with the sIVa-sIVb β-hairpin loop, with the sIVa strand (Y369Y370S371) located in the center of the binding interface. (B) Binding of MEDI3622 to TACE alanine mutants. Two stretches of amino acids were mutated into alanines, including Y369Y370S371 (sIVa strand, the center of the binding interface) and N377I378Y379 (sIVb strand, peripheral to the binding interface). The alanine variants were expressed as soluble proteins and their binding profiles with MEDI3622 were characterized using SPR. Binding was calculated as % binding compared to wild type TACE after normalization of expression levels using the following formula: [(Response TACE variants MEDI3622/Response TACE wildtype MEDI3622)/(Response TACE variants polyAb/Response TACE wildtype polyAb)] *100. Binding of MEDI3622 to TACE was abolished when mutating residues Y369Y370S371 to alanines, while its binding was retained upon mutating residues N377I378Y379. Results represent the means of 3 independent experiments with error bars indicating standard deviations.
Figure 4. Proposed binding mode of MEDI3622. (A) Three-dimensional model of MEDI3622 bound to TACE. The identified epitope of MEDI3622 (P366-N381) (cyan) adopts a β-hairpin loop conformation projecting from the central body of M-domain (magenta). TACE residues Y370 and Y379 (cyan) along with conserved histidines H405, H409, H415 (yellow) are shown in sticks. The Zn ion is shown as a green sphere. MEDI3622 (VH in orange, VL in beige) binds to TACE through interacting with the sIVa-sIVb β-hairpin loop, with the sIVa strand (Y369Y370S371) located in the center of the binding interface. (B) Binding of MEDI3622 to TACE alanine mutants. Two stretches of amino acids were mutated into alanines, including Y369Y370S371 (sIVa strand, the center of the binding interface) and N377I378Y379 (sIVb strand, peripheral to the binding interface). The alanine variants were expressed as soluble proteins and their binding profiles with MEDI3622 were characterized using SPR. Binding was calculated as % binding compared to wild type TACE after normalization of expression levels using the following formula: [(Response TACE variants MEDI3622/Response TACE wildtype MEDI3622)/(Response TACE variants polyAb/Response TACE wildtype polyAb)] *100. Binding of MEDI3622 to TACE was abolished when mutating residues Y369Y370S371 to alanines, while its binding was retained upon mutating residues N377I378Y379. Results represent the means of 3 independent experiments with error bars indicating standard deviations.CC BY-NC · PubMed Central
Figure 5. Unique binding mode of MEDI3622. (A) The binding mode of MEDI3622 appears different from TACE small molecule and natural protein inhibitors upon structure alignments. (Left) The model of the MEDI3622 (VH orange and VL beige)/TACE (magenta) complex was superimposed to crystal structures of TACE M-domains complexed with small molecule inhibitors (PDB 3LE919 and 3O6420) through the common TACE M-domains. The M-domains for 3LE9 and 3O64 were shown in light pink and pale green and their bound small molecule inhibitors were displayed in yellow and blue sticks, respectively. (Right) The model of the MEDI3622/TACE complex was aligned with the crystal structure of TACE M-domain (light pink) bound to the N-terminal domain of TIMP-3 (blue) (PDB 3CKI). (B) Concurrent binding of MEDI3622 and TIMP-3 to TACE. The concurrent binding of MEDI3622 and TIMP-3 to TACE was assessed using a “sandwich”-like binding assay by Octet. Streptavidin Octet sensors were immobilized with biotinylated MEDI3622 or TIMP-3 (1st response), then incubated with TACE ECD or buffer (2nd response), and lastly followed with TIMP-3 or MEDI3622 (3rd response).
Figure 5. Unique binding mode of MEDI3622. (A) The binding mode of MEDI3622 appears different from TACE small molecule and natural protein inhibitors upon structure alignments. (Left) The model of the MEDI3622 (VH orange and VL beige)/TACE (magenta) complex was superimposed to crystal structures of TACE M-domains complexed with small molecule inhibitors (PDB 3LE919 and 3O6420) through the common TACE M-domains. The M-domains for 3LE9 and 3O64 were shown in light pink and pale green and their bound small molecule inhibitors were displayed in yellow and blue sticks, respectively. (Right) The model of the MEDI3622/TACE complex was aligned with the crystal structure of TACE M-domain (light pink) bound to the N-terminal domain of TIMP-3 (blue) (PDB 3CKI). (B) Concurrent binding of MEDI3622 and TIMP-3 to TACE. The concurrent binding of MEDI3622 and TIMP-3 to TACE was assessed using a “sandwich”-like binding assay by Octet. Streptavidin Octet sensors were immobilized with biotinylated MEDI3622 or TIMP-3 (1st response), then incubated with TACE ECD or buffer (2nd response), and lastly followed with TIMP-3 or MEDI3622 (3rd response).CC BY-NC · PubMed Central
Figure 6. Structure alignment of the M-domain structures of TACE and other ADAMs, ADAMTSs and MMPs. Structural alignment of M-domain structures shows that the epitope of MEDI3622, the surface loop of sIVa-sIVb β-hairpin in the TACE M-domain, is a structural feature unique to TACE. The M-domain is shown in magenta for TACE (PDB 3E8R),16 blue for ADAMTS-5 (PDB 3LJT),30 cyan for MMP-9 (PDB 5CUH)31 and gray for ADAM22 (PDB 3G5C).32
Figure 6. Structure alignment of the M-domain structures of TACE and other ADAMs, ADAMTSs and MMPs. Structural alignment of M-domain structures shows that the epitope of MEDI3622, the surface loop of sIVa-sIVb β-hairpin in the TACE M-domain, is a structural feature unique to TACE. The M-domain is shown in magenta for TACE (PDB 3E8R),16 blue for ADAMTS-5 (PDB 3LJT),30 cyan for MMP-9 (PDB 5CUH)31 and gray for ADAM22 (PDB 3G5C).32CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 30

Metadata

Authors
Peng, L., Cook, K., Xu, L., Cheng, L., Damschroder, M., Gao, C., Wu, H., & Dall'Acqua, W. F.
Corresponding author
Peng, Li
Venue
mAbs
Published
2016-09-09
Volume
8
Issue
8
Pages
1598-1605
ISSN
  • 1942-0862 (ISSN-L)
  • 1942-0870
OpenAlex
W2518560246
Cited by
30
References
32
Citations by year
2026: 2 · 2025: 6 · 2023: 2 · 2022: 2 · 2021: 5 · 2020: 3 · 2019: 4 · 2018: 4 · 2017: 2
FWCI
2.89
Type
journal article
Language
en
Open access
Locations
  • mAbs (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Protease and Inhibitor Mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Structural Biology › Enzyme Structure and Function
Keywords
ADAM17, transarterial chemoembolization, antibody specificity, M-domain, beta-hairpin loop, catalytic cleft, antibody-enzyme interaction, antibody design, structural modeling, molecular docking
MeSH terms
ADAM17 Protein, Antibodies, Monoclonal, Humans, Models, Molecular, Epitope Mapping

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.